uniQure N.V. Faces Class Action Lawsuit Over Alleged Securities Fraud: Important Deadlines Imminent
Class Action Lawsuit Filed Against uniQure N.V.
Kessler Topaz Meltzer & Check, LLP has initiated a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased shares during a specified period. This legal action underscores serious allegations regarding misrepresentation of the company's gene therapy developments, particularly concerning Huntington's disease treatment.
Overview of the Class Action
The lawsuit, titled Scocco v. uniQure N.V., et al., has been filed in the Southern District of New York concerning securities fraud. The critical timeline of the case revolves around shares bought between September 24 and October 31, 2025. Investors are urged to consider participating, with a deadline set for April 13, 2026, to seek lead plaintiff status.
Allegations of Mismanagement
The core of the allegations rests on uniQure's purported inaccuracies regarding its clinical trials and the approval process for its lead drug candidate, AMT-130. This innovative gene therapy aimed at slowing Huntington’s disease progression has faced scrutiny due to claims that uniQure misled investors about the efficacy and regulatory approval timeline of the drug. Specifically, the lawsuit claims:
1. Misrepresentation of Clinical Trials: The design of uniQure's pivotal study was reportedly not fully approved by the FDA, leading to doubts about the efficacy claims made by the company.
2. Omission of Critical Information: Statements made by uniQure about the drug's prospects were alleged to lack a basis in reality, particularly regarding the likelihood of a necessary delay in the Biologics License Application (BLA) process.
3. Impact on Share Prices: The share price of uniQure dropped significantly after the company acknowledged that its data may not adequately support its BLA submission to the FDA, resulting in a plummet of over 49% on November 3, 2025.
What You Should Know
For those who invested in uniQure shares during the class period, it is crucial to understand your legal options. Potential lead plaintiffs have until April 13, 2026, to file for recognition in the lawsuit. Taking action may involve:
- - Contacting legal counsel to discuss your options without any obligation or cost.
- - Filing a motion to be considered as a lead plaintiff, which could give you a role in directing the proceedings.
- - Staying informed about the lawsuit’s developments through Kessler Topaz Meltzer & Check, LLP.
Taking Action
If you are among those who acquired uniQure shares and believe you may have faced financial losses due to the alleged misrepresents surrounding the AMT-130 drug, it is advisable to reach out to Kessler Topaz Meltzer & Check, LLP. The firm specializes in securities fraud class actions and offers a free consultation to help determine your eligibility for relief under this lawsuit.
Conclusion
Investing in biotech firms can be particularly risky due to the complexities of drug development and regulatory processes. While the class action against uniQure N.V. unfolds, affected investors should stay vigilant and seek expert legal advice to protect their interests. For further information regarding this lawsuit and to explore recovery options, visit Kessler Topaz Meltzer & Check.
This summary serves to inform investors about legal proceedings involving uniQure N.V. and should not be taken as legal advice.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.